Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 564
- Registration Number
- NCT00422058
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norwich, United Kingdom
Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00419718
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 196
- Registration Number
- NCT00411892
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin
Not Applicable
Completed
- Conditions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00410033
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Linköping, Sweden
A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00400283
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 560
- Registration Number
- NCT00399711
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, San Juan, Puerto Rico
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 264
- Registration Number
- NCT00395746
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT00393718
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 263
- Registration Number
- NCT00383877
Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 419
- Registration Number
- NCT00365170
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Worcester, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath